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Introduction: The TH17 immune response plays a central role in the
pathogenesis of autoimmune diseases, implicating the TH17 “master
cytokine” IL-17A as the critical mediator of diseases such as human
and experimental crescentic glomerulonephritis (GN). However, the
relative importance of additional TH17 effector cytokines,
including IL-17F, in immune-mediated tissue injury remains to be
fully elucidated.
Methods: Here, we used a mouse model of acute crescentic GN
(nephrotoxic Nephritis) including interventional studies using IL-
17F-gene-deﬁcient mice, IL-17F-neutralizing antibodies, as well as
adoptive cell transfer experiments into Rag1-/- mice. Moreover, also
in the chronic model of pristane induced systemic lupus, IL-17F-
deﬁcient mice were analyzed.
Results: In a mouse model of acute crescentic GN, we identiﬁed
CD4+ T cells and T cells as the major cellular source of IL-17F in the
inﬂamed kidney. In our studies using IL-17F-gene-deﬁcient mice as
well as IL-17F-neutralizing antibodies, and adoptive cell transfer
experiments into Rag1-/- mice we demonstrated that CD4+ T cell-
derived IL-17F drives renal tissue injury in acute crescentic GN.
Moreover, also in the chronic model of pristane induced systemic
lupus, IL-17F-deﬁcient mice developed less severe disease with
respect to survival and renal injury. Finally, we show that IL-17F
induced expression of the chemokines CXCL1 and CXCL5 in kidney
cells, which recruited destructive neutrophils.
Conclusions: In conclusion, using gene-deﬁcient mice, neutralizing
antibodies and adoptive cell transfer experiments, we demonstrate
for the ﬁrst time that IL-17F promotes kidney injury in acute and
chronic experimental glomerulonephritis. Our data, which chal-
lenge the paradigm of IL-17A as being the unique TH17 master
cytokine, might be of direct importance for future anti- TH17/IL-17
treatment strategies in human autoimmune diseases.
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Introduction: Chronic kidney disease (CKD) affects around 10% of
the western population and is a major risk factor for cardiovascular
mortality. Regardless of the type of primary injury, glomerular
damage regularly results in progressive glomerulosclerosis with
proteinuria and deteriorating kidney function. Over the last years,
innate lymphoid cells (ILC) have been shown to play an important
role in the immune system’s response to different forms ofKidney International Reports (2016) 1, S1–S22infectious and non-infectious pathologies. Especially, IL-5- and IL-
13-producing type 2 ILC (ILC2) have been implicated in repair
mechanisms with the aim of restoring tissue integrity after injury.
Methods: ILC populations in the human and murine kidney were
analysed by ﬂow cytometry. ILC2 were expanded in mice by
treatment with IL-33. The effect of IL-33-mediated ILC2 expansion
was tested in a mouse model of progressive glomerulosclerosis that
is induced in BALB/c mice by injection of adriamycin.
Results: In the present study, we show that ILC populations are
present in the chronically inﬂamed human kidney. A detailed
characterization of kidney-residing ILC populations in mice
revealed that ILC2 are the most abundant ILC subtype in the mouse
kidney. Short-term IL-33 treatment lead to a sustained expansion of
IL-33R+ kidney ILC2 and ameliorated progressive glomerulo-
sclerosis and attenduated the loss of kidney function induced by
Adriamycin-injection in BALB/c mice. The IL-33 effect was inde-
pendent of T and B cells and depletion of ILC in IL-33 treated mice
abrogated the IL-33-mediated protection from progressive CKD.
The tissue-protective mechanisms employed by IL-5- and IL-13-
producing ILC2 included enhanced activation of alternatively
activated macrophages, recruitment of eosinophils and limitation of
neutrophil inﬂux by downregulation of neutrophil-attracting
chemokines.
Conclusions: In summary, we show that kidney-residing ILC2 can
be effectively expanded by IL-33 in the mouse kidney and are
central regulators of renal repair mechanisms. The presence of ILC
in the human kidney tissue identiﬁes ILC as attractive therapeutic
targets for chronic kidney disease in humans.
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Introduction: Acute kidney injury (AKI) is among the most
frequent causes for renal damage and associated with signiﬁcant
increase of morbidity and mortality. In rodent models for AKI it
was demonstrated that immune cells time dependently contribute
to tissue damage and repair, however there is a lack of data for
human AKI.
Methods: Urine of patients with AKI was processed and prepared
for ﬂow cytometry within 6 hours after acquisition. Cell counts of
immune and renoparenchymal cells were measured using ﬂow
cytometry. Kinetics of diverse cell subsets were investigated over
two weeks past renal failure.
Results: Renal epithelial cell numbers are increased shortly after
renal insult and decrease with recovery of the patients. They
correlate with creatinine and AKI stadium. Neutrophils (CD66b+),
Macrophages (CD36+, CD14+) and T cells (CD3+CD4+ and
CD3+CD8+) were detected in the urine of patients with AKI. While
urinary numbers of renal epithelial cells and neutrophils decreasedS19
TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016with resolution of AKI, we observed a persistence of macrophages
and T cells (>10days).
Conclusions: The amount of renal epithelial cells in the urine seems
to directly reﬂect tissue damage in AKI. Immune cells can be
monitored in the urine of patients with AKI and persisted longer
than the renal injury itself. This suggests that immune cells
participate in mediating damage and tissue repair in human AKI.
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Introduction: The mechanism of injury to podocytes in focal
segmental glomerulosclerosis (FSGS) remains unclear. Both B7.1
(CD80) and suPAR have been proposed to cause FSGS but these
ﬁndings have not been validated. To survey these markers as po-
tential mediators of podocyte injury and as an aid to histologic
diagnosis of FSGS we evaluated the immunohistochemical expres-
sion of (1) B7-1 and suPAR in native and transplant kidney bi-
opsies, and (2) suPAR in an experimental mouse model of FSGS.
Methods: Consecutive kidney biopsies from the surgical pathology
ﬁles were selected for study groups of FSGS (n¼10) and early post-
transplant recurrent FSGS (n¼10). Native kidney biopsies with
membranous nephropathy (MN) (n¼10) and minimal change dis-
ease (MCD (n¼5), and 6 month post-transplant protocol biopsies
with normal morphology [n¼10] served as controls. Immunostains
for B7.1 and suPAR were performed on formalin-ﬁxed parafﬁn-
embedded and frozen sections with immunoperoxidase (IHC) or
immunoﬂuorescent (IF) methodology and the localization of the
positive signal was determined via co-stain with podocyte marker
synaptopodin. Appropriate positive method controls were avail-
able. In addition, uPAR expression was assessed in the kidneys of
wild type and suPAR deﬁcient (suPAR -/-) mice infused with
suPAR. The mouse kidneys were also evaluated by electron mi-
croscopy in conjunction with renal functional studies.
Results: B7.1 was not expressed in native kidneys with FSGS or
MCD or in transplant kidneys with recurrent FSGS. In MN, B7.1
was localized only to the immune deposits. No apparent suPAR
immunoreactivity was present in native kidneys or recurrent FSGS.
suPAR infusion did not produce proteinuria or effacement of
podocytes in wild type or suPAR deﬁcient mice. uPAR was
detected by IHC along the glomerular endothelial cells but not in
podocytes in wild type mice while uPAR stains remained negative
in suPAR deﬁcient mice even after suPAR injection.
Conclusions: The data suggest that B7.1 and suPAR may not play a
signiﬁcant role in podocyte injury in native and transplant kidneys
with FSGS. B7.1 and suPAR immunostains have a limited value as
diagnostic immunophenotypical markers in routine kidney biopsies
with FSGS and recurrent FSGS post-transplant.
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Introduction: The relevance of oxidative stress in systemic lupus
erythematosus (SLE) in humans is not fully understood. Moreover,
none of the previous studies have speciﬁcally studied the impact of
oxidative stress in patients of lupus nephritis. We conducted this
study to evaluate the markers of oxidative stress in patients of SLE
with or without lupus nephritis and to correlate them with clinical
presentation, disease activity, and type & severity of renal
manifestations.
Methods: This was a prospective study including patients diag-
nosed to have SLE on the basis of ACR criteria. The study partic-
ipants were divided into two groups depending on presence or
absence of renal involvement, which was deﬁned as either abnor-
malities in renal function test (serum creatinine$1.2mg/dl) or urine
examination (urine protein excretion $500mg/day or presence of
RBCs in urine) along with renal biopsy evidence of lupus nephritis.
After inclusion, patient’s particulars were noted including clinical
manifestations, investigations, SLE Disease Activity Index (SLE-
DAI), details of renal involvement, renal biopsy, treatment received
and the outcome. In both the groups, an additional 5 ml of venous
blood sample was drawn after overnight (8-10 hours) fasting for
analyzing the markers of oxidative stress. We studied Malondial-
dehyde (MDA) and Isoprostane as markers of lipid peroxidation;
reactive nitrogen intermediates (RNI) as markers of oxidative pro-
tein damage; 8-hydroxy deoxy guanosine as marker of oxidative
DNA damage and Superoxide dismutase (SOD) as a marker of
antioxidant activity.
Results: During the study period a total of 120 cases were included
(60 without lupus nephritis, 60 with lupus nephritis). The mean age
of study population was 29  9 years and 115 were females.
SLEDAI was signiﬁcantly higher in patients with nephritis as
compared to non-nephritis group. The mean values of serum MDA,
8-Isoprostane, 8-Hydroxy 2-deoxyguanosine and RNI were signif-
icantly higher in nephritis group, while there was no difference in
the levels of SOD. Signiﬁcant positive correlations were observed
between RNI and SLEDAI score (r ¼ 0.333, p<0.01), and MDA and
SLEDAI score (r ¼ 0.269, p<0.01), while none of the markers
showed signiﬁcant correlation with serum creatinine. There was no
signiﬁcant correlation between these markers and severity of renal
dysfunction, while 8-Hydroxy 2-deoxy guanosine levels showed
signiﬁcant negative correlation with degree of proteinuria (r¼
-0.345; p value 0.007). MDA levels were signiﬁcantly higher in
patients with proliferative lupus nephritis as compared to non
proliferative nephritis. During six months follow-up, we noted 7
deaths in nephritis group as compared to none in non-nephritis
group. The mean value of 8-Hydroxy 2-deoxy guanosine was
signiﬁcantly higher in those who died; however there was no sig-
niﬁcant difference in other oxidative markers.
Conclusions: SLE patients with nephritis have higher levels of
oxidative stress. Increased oxidative stress in nephritis patients
correlates more with SLEDAI than with type or severity of renal
dysfunction.
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